Patents Examined by Amy H. Bowman
  • Patent number: 11946051
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: April 2, 2024
    Assignee: Tego Science Inc.
    Inventors: Saewha Jeon, Ho Yun Chung, Na Ra Oh, Yun Hee Kim, Jikhyon Han, Hyun Ah Moon
  • Patent number: 11946049
    Abstract: Provided are hybrid tRNA/pre-miRNA molecules, e.g., comprising a single tRNA and one, two or more pre-miRNA molecules, useful for the production and therapeutic delivery of an inserted RNA sequence, e.g., one or more miRNAs. Also provided are liposomes and nanoparticles that include the hybrid tRNA/pre-miRNA molecules. Methods of treating cancer by administration of the hybrid tRNA/pre-miRNA molecules are also provided.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: April 2, 2024
    Assignee: The Regents of the University of California
    Inventors: Aiming Yu, Pui Yan Ho, Meijuan Tu, Joseph L. Jilek, Qianyu Zhang, Hannah E. Petrek
  • Patent number: 11931375
    Abstract: The present disclosure relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and delivery methods for the treatment of spinal cord related disorders including ALS.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: March 19, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Holger Patzke, Qingmin Chen, Jenna Carroll Soper
  • Patent number: 11932850
    Abstract: Described herein are compositions that inhibit/degrade STAT3, and methods of using such compositions for chemoprevention of non-small cell lung cancer (NSCLC).
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: March 19, 2024
    Assignee: Jill M. Siegfried, LLC
    Inventor: Jill M. Siegfried
  • Patent number: 11932854
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: March 19, 2024
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • Patent number: 11920133
    Abstract: The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: March 5, 2024
    Assignee: University of Massachusetts
    Inventors: Terence Flotte, Christian Mueller, Phillip D. Zamore
  • Patent number: 11920152
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: March 5, 2024
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, James Angstman, Shengdar Tsai
  • Patent number: 11911403
    Abstract: The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophic epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: February 27, 2024
    Assignee: Sarepta Therapeutics, Inc.
    Inventor: Dan V. Mourich
  • Patent number: 11911409
    Abstract: An object of the present invention is to develop a novel treatment method for chronic diseases for which conventional treatment methods are either ineffective or for which efficacy is low. The present invention provides a pharmaceutical composition for the treatment and/or prevention of an inflammatory chronic disease that is used in combination with a biological preparation that inhibits leukocyte tissue invasion. The pharmaceutical composition of the present invention contains as an active ingredient thereof siRNA suppressing the expression of CHST15 gene that contains a structure formed by the hybridization of RNA containing the base sequence represented by SEQ ID NO: 1 with RNA complementary thereto.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: February 27, 2024
    Assignee: STELIC INSTITUTE & CO., INC.
    Inventor: Hiroyuki Yoneyama
  • Patent number: 11911410
    Abstract: Disclosed are nucleic acid oligomer compounds and to their use in compositions and methods for inhibiting proliferation, survival or viability of cancer cells including prostate, lung, pancreatic, breast, cervical and bone cancer cells.
    Type: Grant
    Filed: November 7, 2022
    Date of Patent: February 27, 2024
    Assignee: Repluca PTY LTD
    Inventors: Derek Richard, Kenneth O'Byrne, Laura Croft, Sam Beard
  • Patent number: 11905308
    Abstract: The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2?-position and the 4?-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: February 20, 2024
    Assignee: OSAKA UNIVERSITY
    Inventors: Satoshi Obika, Kosuke Ito, Takaki Habuchi, Masahiko Horiba
  • Patent number: 11898147
    Abstract: The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.
    Type: Grant
    Filed: September 6, 2021
    Date of Patent: February 13, 2024
    Assignee: NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Tsung-Hsien Chuang, Jen-Chih Tseng, Jing-Xing Yang, Yi-Ling Liu
  • Patent number: 11891605
    Abstract: Disclosed herein are methods, compositions, polynucleic acid polymers, assays, and kits for inducing processing of a partially processed mRNA transcript to remove a retained intron to produce a fully processed mRNA transcript that encodes a full-length functional form of a protein. Also described herein are methods and compositions for treating a disease or condition characterized by impaired production of a full-length functional form of a protein or for treating a disease or condition characterized by a defective splicing in a subject.
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: February 6, 2024
    Assignee: University of Southampton
    Inventors: Igor Vorechovsky, Jana Kralovicova
  • Patent number: 11884919
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: January 30, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • Patent number: 11873489
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: January 16, 2024
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Lucas Bethge, Judith Hauptmann, Christian Frauendorf, Adrien Weingärtner
  • Patent number: 11873496
    Abstract: The invention relates to methods of modulating the expression of one or more genes in a cell by modulating the multimerization of a transcription factor and/or modulating the formation of enhancer-promoter DNA loops, and thereby modulating the expression of the one or more genes. The invention also relates to treating diseases and conditions involving aberrant gene expression by modulating the multimerization of a transcription factor and/or modulating the formation of enhancer-promoter DNA loops. The invention also relates to methods for screening for compounds that modulate expression of one or more genes in a cell.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: January 16, 2024
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Richard A. Young, Abraham S. Weintraub, Charles H. Li, Alla A. Sigova
  • Patent number: 11865090
    Abstract: The present invention provides compositions having one or more agents capable of increasing expression of one or more endogenous tumor suppressive mi RNAs in one or more producing cells, such that the endogenous mi RNAs can affect one or more target cancer cells. Further provided are method and uses thereof for treating cancer.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: January 9, 2024
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Eithan Galun, Hilla Giladi, Chofit Chai, Nofar Rosenberg, Dayana Yaish, Zohar Shmuelian
  • Patent number: 11865134
    Abstract: The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: January 9, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gaurang Patel, Ying Hu, Kavita Praveen, Giovanni Coppola, Goncalo Abecasis, Aris Baras, Carmelo Romano
  • Patent number: 11857563
    Abstract: This current invention provides methods and agents for preventing and treating autoimmune and lymphoproliferative disease by targeting pathogenic age-associated B cells as well as methods of detecting these pathogenic age-associated B cells as a method of diagnosing and predicting autoimmune disease and other lymphoproliferative and chronic inflammatory disorders. The current invention also provides targets for drug development and basic research for autoimmune diseases and other lymphoproliferative and chronic inflammatory disorders.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: January 2, 2024
    Assignee: NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY
    Inventors: Alessandra Pernis, Michela Manni
  • Patent number: 11857633
    Abstract: Provided herein are, inter alia, nucleic acid conjugates including a non-cell penetrating ribonucleic acid compound attached at its 3? end to a phosphorothioate polymer. Attachment of the phosphorothioate polymer to the non-cell penetrating ribonucleic acid conveys stability to and allows for efficient intracellular delivery of the non-cell penetrating ribonucleic acid. The nucleic acid conjugates provided herein including embodiments thereof are useful, inter alia, for the treatment of cancer, inflammatory disease, and pain.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: January 2, 2024
    Assignee: City of Hope
    Inventors: Andreas Herrmann, Hua Yu